VTGN (VistaGen Therapeutics Inc) שיעור רווח גולמי

Vistagen Therapeutics demonstrates potential through the development of innovative nasal sprays for depression. The average gross margin illustrated by this chart on GURU.Markets confirms the resilience of the model, where the indicator level stands at 67.70. Operational efficiency is based on outsourcing production via CDMO plants, while intellectual capital is maintained through a stock option system for key neurobiologists and clinical experts.
פילוחים אנליטיים ודוחות נתונים של חברת Vistagen (VTGN)

For Vistagen Therapeutics (VTGN), which operates in the defensive neuropsychiatry sector, financial stability depends on the efficiency of managing drug development costs. An analysis of the annual gross margin allows for an assessment of the revenue share minus direct production costs, which helps investors identify hidden accounting anomalies and determine the business's actual ability to generate profit regardless of macroeconomic cycles.